Read more
Learn more about TRION
and its unique development approach
Corporate profile
Member of 
BIO Deutschland e. V.
TRION Pharma and its affiliate TRION Research were founded in 1998 by a group of scientists working with TRION®s managing director Dr Horst Lindhofer. During the 1990s, the team had established a pioneering approach leading to the development of the first Triomab® prototypes at the Helmholtz Zentrum München in Munich, Germany. Following the incorporation of TRION, all rights and related intellectual property regarding Triomab® antibodies were acquired from Helmholtz Zentrum München.
Since then, the company has steadily expanded in terms of size, portfolio, and production capacities.
| 1998 |  |
Closure of collaboration agreement with Fresenius |
| 2001 | |
Set up and GMP certification of first production plant |
|
Start of first clinical trial with most advanced compound Removab®/catumaxomab (Phase I/II; malignant ascites) | |
| 2003 | |
Start Phase I clinical trial rexomun®/ertumaxomab |
| 2004 | |
Start Phase II/ III clinical trial of Removab®/catumaxomab |
| 2006 | |
Start Phase II clinical trial rexomun®/ertumaxomab (metastatic breast cancer) |
|
Start Expansion of GMP production capacities | |
|
EU Commission granting Orphan Drug Designation for Removab®/ catumaxomab in ovarian cancer and gastric cancer | |
|
FDA granting Orphan Drug Designation for Removab®/ catumaxomab in Malignant Ascites | |
| 2007 | |
Start Phase I/II clinical trial Lymphomun/FBTA05 |
|
Favorable final results of Phase II/ III clinical trial of Removab®/ catumaxomab | |
|
TRION Pharma grows to more than 100 employees | |
|
EU marketing authorization application for Removab®/catumaxomab in malignant ascites by partner Fresenius | |
| 2008 | |
TRION's 10th anniversary |
|
GMP certification of second production plant | |
| 2009 | |
· EU approval for Removab®/catumaxomab in malignant ascites |
Today, TRION has three product candidates in all three stages of clinical development (I-III) addressing several different tumor indications including ovarian, gastric, breast and blood cancer. A pivotal Phase II/ III study with Removab® in patients suffering from malignant ascites led to EU approval of the first Triomab® representative in 2009.